Eunyoung Suh

机构：Janssen (United States)

发表论文 12 篇 · 总被引 569 次 · h-index 6

代表论文

• Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (2018 · New England Journal of Medicine · 被引 248)
• Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin (2015 · Journal of the American College of Cardiology · 被引 181)
• Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study (2019 · Clinical and Applied Thrombosis/Hemostasis · 被引 66)
• Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study (2021 · American Heart Journal · 被引 44)
• Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials (2020 · Thrombosis and Haemostasis · 被引 19)
• Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older (2021 · Journal of Thrombosis and Haemostasis · 被引 7)